**Why carry out this study?**

- Myelodysplastic syndromes (MDS) are a group of hematopoietic disorders that particularly affect the elderly population.
- Decitabine is a hypomethylating agent that has been approved for the treatment of a variety of hematopoietic disorders, including MDS, in the United States.
- This open-label, randomized, phase 3 study aimed to evaluate the efficacy, safety and pharmacokinetics of decitabine in Chinese patients with MDS.

**What was learned from the study?**

- Decitabine significantly improved the response rate and demonstrated favorable efficacy, particularly in patients aged >60 years.
- The safety and pharmacokinetic profile of decitabine was consistent with the data from the global studies.